• Home Blog Endocrinology and metabolic disorders

Endocrinology and Metabolic Disorders

pharma-news-for-corstasis-amneal-greenwich

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Lion TCR Secures Triple FDA Milestones with IND Clearance for Chronic Hepatitis B; Corstasis Therapeutics Wins FDA Approval for ENBUMYST Nasal Spray to Treat Edema in CHF, Liver, and Kidney Disease; Amneal Gains FDA Approval for Sodium Oxybate Oral Solution in Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness; Greenwich LifeSciences’ GLSI-100 Granted FDA Fast Track Designation; Akeso’s Ligufalimab Granted FDA Orphan Drug Designation for Acute Myeloid Leukemia

Explore More...
pharma-news-for-eisai-travere-sanofi

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

10 Powerful Applications of Mobile Clinics Around the World Bridging the Healthcare Gap

10 Powerful Applications of Mobile Clinics Around the World Bridging the Healthcare Gap

pharma-news-for-madrigal-valneva-protagonist

Madrigal Wins EU Approval for REZDIFFRA in MASH With Liver Fibrosis; Valneva Faces FDA License Suspension for Chikungunya Vaccine IXCHIQ; Coya Secures FDA IND Clearance for COYA 302 in ALS Treatment; Rusfertide Earns FDA Breakthrough Therapy Designation for Polycythemia Vera; Crinetics Gains FDA Orphan Drug Status for Atumelnant in Congenital Adrenal Hyperplasia

growth-hormone-deficiency-treatment-landscape

Overcoming Adherence Challenges in Growth Hormone Deficiency Treatment: The Promise of Long-Acting and Oral Therapies

Small interfering RNA (siRNA) Therapeutics

Small interfering RNA (siRNA) Therapeutics

pharma-news-for-ascendis-apellis-entera

Ascendis Pharma’s SKYTROFA Approved by FDA for Adult Growth Hormone Deficiency; Apellis Wins FDA Approval for EMPAVELI in C3G and IC-MPGN Treatment; FDA Approves PTC Therapeutics’ Sephience for Phenylketonuria; MAIA Biotechnology’s Ateganosine Gets FDA Fast Track for Non-Small Cell Lung Cancer; Entera Bio Gets FDA Nod on BMD as Primary Endpoint for Phase III Osteoporosis Study

orforglipron-phase-iii-achieve-1-trial

Orforglipron at American Diabetes Association (ADA): Pioneering the Next Generation of Oral, Nonpeptide GLP-1 Therapies

vx-880-101-forward-trial

Durable Glycemic Control and Elimination of Exogenous Insulin Use with Zimislecel (VX-880) in Patients with Type 1 Diabetes (T1D)—VX-880-101 (FORWARD)

maritide-phase-ii-trial

Once-monthly MariTide for the Treatment of Obesity in People with or without T2D: A 52-Week Phase II Study

metseras-glp-1-receptor-agonist-met-097i

MET-097i: A Fully Biased Ultra-long Acting GLP-1 Receptor Agonist

cagrisema-phase-iiia-redefine-trials

CagriSema Shows Strong Dual-Hormone Promise in Obesity and T2D: Key Findings from REDEFINE Trials

evolocumab-fourier-trial

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With T1D: Insights From the FOURIER Trial

pharma-news-for-merck-kalvista-mustang

Merck’s WINREVAIR Granted FDA Priority Review for Pulmonary Arterial Hypertension; KalVista’s EKTERLY Approved by FDA as First Oral On-Demand Therapy for Hereditary Angioedema; Fujifilm’s FF-10832 Receives FDA Orphan Drug Designation for Biliary Tract Cancer; Mustang Bio’s MB-101 Granted FDA Orphan Drug Designation for Glioblastoma and Astrocytomas; Denali’s Tividenofusp Alfa Accepted for FDA Priority Review for Hunter Syndrome

pharma-news-for-amylyx-cellectar-merck

Amylyx’s AMX0114 Fast Tracked by FDA for ALS; Cellectar’s Iopofosine I 131 Granted FDA Breakthrough in Waldenstrom Macroglobulinemia; YolTech’s YOLT-101 Clears FDA IND for Familial Hypercholesterolemia; Oncovita’s MVdeltaC Gets FDA Orphan Tag for Pleural Mesothelioma; Merck’s ENFLONSIA Approved for RSV Prevention in Infants

Mobile Apps for Chronic Diseases Management

Assessing the Growing Role & the Demand of Chronic Disease Management Apps

medtech-news-for-fujirebio-stryker-abbott

FDA Clears Fujirebio’s Lumipulse® G Plasma Test for Detecting Alzheimer’s-Linked Amyloid Pathology; Stryker Gains FDA Clearance for OptaBlate® BVN System to Treat Chronic Low Back Pain; Abbott Unveils Clinical Evidence Linking Libre® CGM to Reduced Cardiovascular Events in Diabetes; GE HealthCare Launches AI-Based CleaRecon DL for Enhanced 3D Reconstruction in Interventional Suites; Philips Advances Cardiac Care with Launch of RADIQAL Clinical Study and Real-Time 3D Intracardiac Imaging Catheter in Europe

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader